|
|
|
|
|
市場調査レポート
感染病診断における分子診断技術の利用
An Evaluation of Product Usage for Molecular Testing within Infectious Diseases
|
当商品の販売は、2011年07月19日を持ちまして終了しました。
The new report by HBS Consulting examines the reality of 221 laboratories and
hospitals in 11 European countries and provides you with following information:
Molecular Tests
- Description of laboratory landscape per country
- the number of performed tests for 47 pathogens
- which products, technologies and manufacturers are used per pathogen .
determine current laboratory equipment that is used for microbiology testing
- Unmet needs
- which tests, technologies and products show the most promising market
opportunities in the short to medium term
- market potential in volume per test, technology and country
- regulatory issues per country (legislation, reimbursement
Product Value Proposition
The study will allow the owner of the information to:
- Assess current market realities in terms of currently performed tests /
Used technologies at an unparalleled level of segmentation
- Get detailed knowledge on suppliers of molecular test kits / equipment,
(by segmentation criteria)
- Reflect the current situation not only at a specific point in time, but
monitor trends over a period of time (both in terms of market participants
as well as system types)
- Model market and own sales forecasts on system types based on investment
plans of customers
- Reflect the expected behaviour of buyers, not just the expectations of
sellers; but by the motivations of buyers.
- Model market forecasts on associated product lines (e.g. PCR Cycler, NAT
related devices) based on procedure data
- Make decisions regarding the market entry/marketing strategy
Respondents have been chosen randomly in order to guarantee that the
respondents reflect the real market situation. However the definition of the
project required the focus on such institutions that perform molecular testing
particularly.
Table of Contents(Germany)
1.1 Project Objectives5
1.2 Definitions7
1.3 German HealthCareSystem and Reimbursement9
1.4 German Laboratory Landscape14
1.5 RespondentPopulation Germany15
2.1 Sexual TransmittedDiseases(STD)17
- ChlamydiaTrachomatis19
- Neisseria21
- HIV22
- HCV23
- Group B Streptococcus24
- HSV25
2.2 Mycobacteria25
- MycobacteriaTuberculosis28
- MycobacteriaAvium29
- Mycobacteria?NA Purification31
2.3 AtypicalPneumoniae32
- Bordetella33
- Legionella33
- Chlamydiasp.34
- MycoplasmaPneumoniae35
2.4 Cytomegalovirus(CMV)36
- CMV ?Qualitative Tests37
- CMV ?Quantitative Tests37
2.5. ViralMeningitis38HSV 1 & 239
- Enterovirus41
- West NileVirus (WNV)41
- Epstein BarrVirus (EBV)42
- VZV43
2.6 RespiratoryViruses44
- SARS45
- Adenovirus46
- Influenza A46
- Influenza A&B47
- RSV48
- Parainfluenza48
2.7 HPV49
2.8 ChronicMeningitis50
2.9 BacterialMeningitis53
- NeisseriaMeningitis54
- HaemophilusInfluenza54
- Pneumococcae55
- Listeria55
- Enterobacteria56
2.10 Tick Born Encephalitis56
2.11 AntibioticResistantBacteria59
2.12 Candida61
3. Equipment & Purchase63
3.1 CurrentInstallations& Financingof Laboratory Equipment63
- Cobas Amplicor, Roche64
- Light Cycler, Roche64
- ABI PRISM, AppliedBiosystems64
- RotorGene, CorbettResearch64
- OtherCycler65
- OtherDevices/Manufacturers66
3.2 Budget Resources67
3.3 WhoisInvolvedin PurchasingDecisions70
3.4 Howdo LaboratoriesPurchase72
3.5 CriteriaInfluencea PurchasingDecision74
3.6 WhatareLaboratoriesWillingto PayforNew Tests? 75
4. Market Sizesand Market Shares 76
4.1 Market VolumesforSelectedPathogens76
- STD77
- MycobacteriaTuberculosis78
- AtypicalPneumonia78
- CMV79
- ViralMeningitis80
- RespiratoryViruses81
- HPV82
- MRSA82
4.2 Market Shares83
5. Market Trends 85
5.1 Problems withMolecularDiagnostics85
5.2 ExpectedGrowth per Segment86
6.3 OtherGrowth Areas90
5.4 Drivers forMolecularDiagnostics91
5.5 RestraintsforMolecularDiagnostics92
6. PoliticalInfluences93
6.1 Changesof ReimbursementPolicy93
6.2 Influenceof the EU IVD Act94
|
 |
